Two previous studies demonstrated that VHL-CRBN heterodimerizing PROTACs promote CRBN degradation, but not VHL degradation, and that treatment with these PROTACs causes resistance of multiple myeloma cells to IMiDs31,32. Here, VHL is linked to plasma cell myeloma.